Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Intellectus Partners LLC

Intellectus Partners LLC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 47.4% in the 3rd quarter, Holdings Channel.com reports. The fund owned 21,429 shares of the biopharmaceutical company’s stock after selling 19,330 shares during the period. Intellectus Partners LLC’s holdings in Gilead Sciences were worth $1,797,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of GILD. OneDigital Investment Advisors LLC grew its position in Gilead Sciences by 5.1% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 32,416 shares of the biopharmaceutical company’s stock worth $2,718,000 after purchasing an additional 1,580 shares during the last quarter. ING Groep NV lifted its stake in shares of Gilead Sciences by 38.8% during the third quarter. ING Groep NV now owns 392,685 shares of the biopharmaceutical company’s stock worth $32,923,000 after buying an additional 109,788 shares during the period. Tokio Marine Asset Management Co. Ltd. grew its holdings in shares of Gilead Sciences by 15.4% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 35,439 shares of the biopharmaceutical company’s stock valued at $2,971,000 after buying an additional 4,742 shares during the last quarter. Black Swift Group LLC acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at $419,000. Finally, Curi RMB Capital LLC lifted its position in Gilead Sciences by 0.9% during the 3rd quarter. Curi RMB Capital LLC now owns 87,850 shares of the biopharmaceutical company’s stock worth $7,365,000 after acquiring an additional 805 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Wells Fargo & Company increased their price objective on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Robert W. Baird lifted their price objective on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Barclays increased their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 7th. Finally, Oppenheimer boosted their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $93.10.

Gilead Sciences Trading Down 0.6 %

Shares of Gilead Sciences stock opened at $92.11 on Friday. The company has a current ratio of 1.26, a quick ratio of 0.82 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The firm has a market capitalization of $114.79 billion, a PE ratio of 1,023.44, a P/E/G ratio of 2.85 and a beta of 0.17. The firm’s 50-day moving average price is $86.22 and its 200 day moving average price is $75.69.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter last year, the business posted $2.29 earnings per share. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 4.39 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be paid a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.34%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. This represents a 27.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. This trade represents a 1.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 56,947 shares of company stock valued at $4,968,674. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.